Completed

A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Every 21 Days in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Urogenital Diseases+7

+ Genital Diseases

+ Genital Diseases, Male

Over 19 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
See protocol details

Summary

Principal SponsorGenzyme, a Sanofi Company
Last updated: January 13, 2026
Sourced from a government-validated database.Claim as a partner

This is a Phase II, non-randomized, open label study of ILX651 in patients with hormone-refractory prostate cancer previously treated with docetaxel. Approximately 40 patients will be enrolled in this study that is expected to last 24 months. All patients will be treated with ILX651 administered IV daily for 5 consecutive days every 21 days. The primary objective of this study is to determine the PSA response rate. The secondary objectives are to determine response of measurable disease, duration of response, time to PSA progression, time to treatment failure, survival, safety and tolerability, and pharmacokinetic profile of ILX651.

Official TitleA Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Every 21 Days in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel 
NCT00082134
Principal SponsorGenzyme, a Sanofi Company
Last updated: January 13, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

40 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Male

Biological sex of participants that are eligible to enroll.

Over 19 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesGenital Diseases, MaleGenital Neoplasms, MaleNeoplasmsNeoplasms by SiteProstatic DiseasesProstatic NeoplasmsUrogenital NeoplasmsMale Urogenital Diseases

Criteria

Inclusion Criteria: * Patient has hormone-refractory prostate cancer (HRPC) as evidenced by PSA progression or progression of measurable disease. * Patient has greater than 25% increase in 2 consecutive tests in which the first increase in PSA should occur a minimum of 1 week apart. * Patients on androgen deprivation treatment and will continue on androgen deprivation treatment during study participation except for patients who are post orchiectomy. * Patient has evidence of metastatic disease by positive bone scan or evidence of progressive metastatic disease by CT scan. * Patient has been treated with at least 1 prior hormone therapy or is post orchiectomy. * Patient has been previously treated at a minimum for an 8-week treatment period on a docetaxel-based regimen for metastatic HRPC. * Patient has PSA at least 5 ng/mL or greater. * Patient has testosterone less than 50 ng/dL. * Patient ECOG performance status of 0 or 1. * Patient has life expectancy of greater than 8 weeks. * Patient meets lab values: A. Absolute neutrophil count at least 1,500/mm\^3 or greater; B.Platelet count at least 100,000/mm\^3 or greater; C. Serum creatinine at least 1.5 mg/dL or less or creatinine clearance at least 60 mL/min or greater; D. Bilirubin less than 2.0 mg/dL. E. AST and ALT less or equal to 2.5 times upper limit of normal * Any chemotherapy, major surgery, or irradiation must be completed at least 4 weeks prior to study drug. * Patient recovered from clinically significant toxicities from prior treatment. Exclusion Criteria: * Prior treatment with 2 or more prior chemotherapy regimens. * Concurrent treatment with an estrogen-containing agent including diethylstilbestrol (DES). * Prior flutamide (Eulexin) within past 4 weeks, prior bicalutamide (Casodex) within past 6 weeks, or prior nilutamide (Nilandron) within past 6 weeks. * Prior strontium or samarium or other radioisotope therapy. * Prior radiation therapy to greater than 25% of the bone marrow (e.g., no whole pelvic irradiation is allowed). * Uncontrolled congestive heart failure or angina, patients with a history of myocardial infarction within 2 months of enrollment. * Patients with uncontrolled hypertension. * Pre-existing cardiac, pulmonary, neurologic or other disease that would preclude study participation. * Documented untreated central nervous system (CNS) metastases. However, patients with treated CNS metastases that have been stable are eligible. * Any significant concurrent disease or illness, or psychiatric disorders or alcohol or chemical abuse that would preclude study participation. * Active secondary malignancy except non-melanoma skin cancers. * Known, active infection, or known HIV positive or presence of an AIDS related illness.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 12 locations

Suspended

Arizona Clinical Research Center

Tucson, United StatesSee the location
Suspended

Kansas City Cancer Centers

Lenexa, United States
Suspended

Kansas City Cancer Centers

Overland Park, United States
Suspended

Kansas City Cancer Centers- Central

Kansas City, United States
Completed12 Study Centers